Back to top

TBScience 2019 Submission Guidelines

Submissions are open until 22 July

The 50th Union World Conference on Lung Health is pleased to host TBScience 2019, an official pre-conference event entirely devoted to basic and translational TB research.

Held ahead of the main conference on 29 and 30 October, the pre-conference will be located at the Cyber Convention Centre (five minutes away from the Union World Conference venue, Hyderabad International Convention Centre).

INFORMATION FOR AUTHORS

  • All TBScience 2019 abstracts must be submitted online using the submissions platform, between 17 June and 22 July. Abstracts submitted by email or any alternative method will not be considered.
  • Persons submitting TBScience 2019 abstracts will be notified of acceptance or rejection of their submissions by 20 August 2019.
  • If you represent a UN organisation, please select the name of the organisation from the list available in the drop down menu.
  • A listed co-author other than the corresponding author may register and present the study at the conference. The corresponding author is responsible for the session content. S/he is the contact person for submission and communication purposes and is also responsible for disseminating information related to the session to co-authors.
  • The maximum number of authors and institutions is eight.
  • If all authors belong to a single institution, you do not need to create new affiliations for each author.
  • When submitting, click on “Institutes” to fill in the affiliation field.
  • Please note that alternate language interpretations of presentations will not be provided.

ABSTRACT INFORMATION

THEMES

Abstract submissions, either oral or poster presentations, should be aligned with one of these four session themes:

New diagnostics to reach the missing millions
To reach the “missing” and vulnerable patient populations, including people living with HIV and children, there is a need for novel tests that are rapid, rugged, easy to use and can be done on an easily accessible sample types (e.g. urine, fingerprick blood, saliva) where patients first present to care. Such tests may improve affordability and availability of TB diagnosis and could thus increase the identification of TB cases and reduce TB transmission. This session aims to assess the status of the discovery and development of diagnostic tests in this space, focusing on pathogen biomarkers.

Bacterial evolution
From departing a TB patient’s lung, through arrival in the next susceptible host, transmission poses a key bottleneck in the life of M. tuberculosis. As TB incidence will not decline unless we turn off the tap, new insights in transmission fitness, and its evolutionary determinants, will inform innovative approaches to TB control relevant to immunocompetent as well as immunodeficient hosts.

New strategies in TB therapeutics: It’s time to break the mould!
Emerging new strategies and innovations in the TB therapeutics field prompt a reassessment of our longstanding approaches to TB drug and regimen development. New tools and methods for identifying drug targets, designing regimens intelligently, and for exploring non-antibiotic based, host-directed approaches to curing TB as a means to minimised morbidity and mortality in immunocompetent and immunodeficient patients will be reviewed in this session. It’s time to break the mould!

Prevent infection or prevent disease?
This session will highlight the most recent developments in TB vaccine development and evaluation, following the publication of two seminal and successful phase 2B TB vaccine clinical trials in 2018. This will be followed by in depth discussion of new data on mucosal immunisation in humans and in animal models. The session will be complemented by discussing latest insights into immune corelates of protection against, and risk of developing Mtb infection or TB disease in immunocompetent and immunodeficient hosts.

TEXT

  • The abstract should be in English, and no more than 300 words.
  • Type the title of the abstract in upper and lower case, using capitals only for the first word, acronyms and proper nouns. Titles of more than 25 words (110 characters and spaces) will be truncated.
  • One table or one figure may be included with the abstract.
    • If you wish to submit a table with your abstract, note that it should be no larger than five rows by 10 columns.
    • If you wish to submit a figure with your abstract, note the maximum file size of each graph /image is 5 MB. The maximum pixel size of the graph is 600(w) x 800(h). You may upload graphs in JPG, GIF or PNG format.
    • Recommended resolution: mi 150 dpi, 300 dpi for images, 600 dpi for line art (charts).
    • Important: the graphic content must be clearly legible when previewing the abstract.
    • Low-resolution images will not be included in the Abstract Book.
    • Please note that tables and figures are reproduced in a single column with the abstract and that legibility is the responsibility of the author.
    • We recommend that you use a sans serif (Arial or Calibri) font for clarity.
  • Use the palette of characters provided to insert symbols, accents and special formatting (e.g., italics, bold, β, μ, etc.).
  • Abbreviations and acronyms must be written out in full at the first mention in the text.
  • Authors are responsible for proofreading and submitting an abstract without errors, as they will be reproduced in the form they were submitted.

ORGANISATION

  • Authors are given flexibility with regards to the structure of their abstract.
  • No imposed abstract sections such as Background, Methods, Results and Conclusions are required.
  • It is the responsibility of the author to present the abstract in a cohesive way.

USE OF NON-STIGMATISING LANGUAGE

SUBMISSION PROCESS

SUBMITTING AN ABSTRACT

  • To submit a new abstract, create a user account on the abstract submission platform.
  • Ensure that you carefully read all instructions given on the screen at each step of the process.
  • Do not upload the text of your abstract as an attachment. Abstracts submitted as attachments will not be considered.
  • Please refrain from submitting multiple abstracts on the same topic by varying the authors or under different titles with only minor word changes. In such cases, all of the submissions on that topic will be automatically rejected.

SUBMITTING A POST

The corresponding author will receive an email confirming that the submitted abstract has been received successfully, with an attachment of the submission.

After the abstract has been submitted, it can still be edited. However, please make sure that you submit it in its final version before the deadline.

REVIEW

All submitted abstracts will be sent for peer review by a panel of international experts. The scores will then be submitted to a reviewing committee. Note that decisions of the abstract review committee are final and cannot be appealed.

NOTIFICATION

  • Corresponding authors will be notified of acceptance of their late-breaker sessions by 20 August.
  • Abstracts that are not accepted cannot be reconsidered for review or presentation at the conference.

TO INCLUDE WITH APPLICATION

  • Confirmation that the work has not been previously submitted for consideration to the general portion of the Union World Conference.
  • A request and rationale for travel support, if so desired*.
  • The address, phone and email address where the author may be contacted.

*Note: A number of travel grants are available for presenters of accepted abstracts who require funding to attend the conference. If you intend to request support, an indication of your desire and rationale for consideration for a travel grant must be submitted online together with the abstract. The reviewing committee will be blinded to the request for travel funds.

If you have any questions, contact tbscience@theunion.org 

Submit an abstract for TBScience

Receive Conference News & Updates